Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30

$3.21+0.18 (+5.94%)

Close on Nov 13, 2026Market cap $12.68MP/E –Yield –

Onconetix ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Onconetix's ebitda for the twelve months ending Jun 30, 2026 was -$16.29M. For fiscal 2025 it was -$17.84M.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$17.84M	–
FY2024	Dec 31, 2024	-$55.76M	–
FY2023	Dec 31, 2023	-$35.99M	–
FY2022	Dec 31, 2022	-$13.47M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	-$2.73M	–
Q1 FY2026	Mar 31, 2026	-$10.22M	–
Q4 FY2025	Dec 31, 2025	-$1.28M	–
Q3 FY2025	Sep 30, 2025	-$2.07M	–
Q2 FY2025	Jun 30, 2025	-$1.93M	–
Q1 FY2025	Mar 31, 2025	-$12.57M	–
Q4 FY2024	Dec 31, 2024	-$29.03M	–
Q3 FY2024	Sep 30, 2024	-$2.44M	–
Q2 FY2024	Jun 30, 2024	-$13.41M	–
Q1 FY2024	Mar 31, 2024	-$10.88M	–
Q4 FY2023	Dec 31, 2023	-$22.01M	–
Q3 FY2023	Sep 30, 2023	-$4.49M	–